Skip to main content
Top
Published in: Pituitary 6/2016

01-12-2016

Pituitary tumors in MEN1: do not be misled by borderline elevated prolactin levels

Authors: Alina Livshits, Jelena Kravarusic, Ellie Chuang, Mark E. Molitch

Published in: Pituitary | Issue 6/2016

Login to get access

Abstract

Purpose

The objective of this case report is to demonstrate that the simple expedient of measuring periodic prolactin levels in patients with MEN1 who have modest hyperprolactinemia and normal pituitary MRI scans is insufficient to monitor for the development of pituitary adenomas.

Methods

Review of relevant literature and chart review.

Results

A 25 year old man with known MEN1 manifested by hyperparathyroidism and a gastrin-producing neuroendocrine tumor was found to have a prolactin [PRL] level of 20.0 ng/mL [1.6–16 ng/mL] but a normal pituitary MRI scan. The impression then was that he had prolactinoma too small to be visualized on the MRI. Over the next 3.5 years his PRL levels remained in this mildly elevated range but he then presented with severe headaches and visual field defects. An MRI showed a 3.1 × 1.7 × 1.9 cm pituitary adenoma with compression of the optic chiasm and invasion of the left cavernous sinus. Surgery revealed a gonadotroph adenoma and he subsequently required gamma knife radiotherapy for residual tumor. Postoperative PRL levels were normal.

Conclusions

Small, intrasellar microadenomas may be associated with elevated PRL levels due to possible direct hormone production [prolactinoma] or possibly to interference with portal vessel blood flow. In monitoring hyperprolactinemic MEN1 patients for the development of pituitary adenomas, measurement of PRL levels is insufficient and periodic MRI scans are necessary at a more frequent interval than every 3–5 years. This may also pertain to patients with “idiopathic” hyperprolactinemia.
Literature
1.
go back to reference Thakker RV (2010) Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab 24:355–370CrossRefPubMed Thakker RV (2010) Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab 24:355–370CrossRefPubMed
2.
go back to reference Burgess J, Shepherd J, Parameswaran V, Hoffman L, Greenaway T (1996) Spectrum of pituitary disease in multiple endocrine neoplasia type 1 [MEN 1]: clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred. J Clin Endocrinol Metab 81:2642–2646PubMed Burgess J, Shepherd J, Parameswaran V, Hoffman L, Greenaway T (1996) Spectrum of pituitary disease in multiple endocrine neoplasia type 1 [MEN 1]: clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred. J Clin Endocrinol Metab 81:2642–2646PubMed
3.
go back to reference O’Brien T, O’Riordan D, Gharib H, Scheithauer BW, Ebersold M, van Heerden JA (1996) Results of treatment of pituitary disease in multiple endocrine neoplasia, type 1. Neurosurgery 39:273–279CrossRefPubMed O’Brien T, O’Riordan D, Gharib H, Scheithauer BW, Ebersold M, van Heerden JA (1996) Results of treatment of pituitary disease in multiple endocrine neoplasia, type 1. Neurosurgery 39:273–279CrossRefPubMed
4.
go back to reference Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C, Calender A, Members of the Groupe d’Etude des Neopalsmies Endocriniennes Multiples (2002) Pituitary disease in MEN type 1 [MEN1]: data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 87:457–465CrossRefPubMed Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C, Calender A, Members of the Groupe d’Etude des Neopalsmies Endocriniennes Multiples (2002) Pituitary disease in MEN type 1 [MEN1]: data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 87:457–465CrossRefPubMed
5.
go back to reference Hao W, Skarulis MC, Simonds WF, Weinstein LS, Agarwal SK, Mateo C, James-Newton L, Hobbs GR, Gibril F, Jensen RT, Marx SJ (2004) Multiple endocrine neoplasia type 1 variant with frequent prolactinoma and rare gastrinoma. J Clin Endocrinol Metab 89:3776–3784CrossRefPubMed Hao W, Skarulis MC, Simonds WF, Weinstein LS, Agarwal SK, Mateo C, James-Newton L, Hobbs GR, Gibril F, Jensen RT, Marx SJ (2004) Multiple endocrine neoplasia type 1 variant with frequent prolactinoma and rare gastrinoma. J Clin Endocrinol Metab 89:3776–3784CrossRefPubMed
6.
go back to reference Vierimaa O, Ebeling TML, Kytölä S, Bloigu R, Eloranta E, Salmi J, Korpi-Hyöväti E, Niskanen L, Orvola A, Elovaara E, Gynther A, Sane T, Välimäki M, Ignatius J, Leisti J, Salmela PI (2007) Multiple endocrine neoplasia type 1 in Northern Finland; clinical features and genotype-phenotype correlation. Eur J Endocrinol 157:285–294CrossRefPubMed Vierimaa O, Ebeling TML, Kytölä S, Bloigu R, Eloranta E, Salmi J, Korpi-Hyöväti E, Niskanen L, Orvola A, Elovaara E, Gynther A, Sane T, Välimäki M, Ignatius J, Leisti J, Salmela PI (2007) Multiple endocrine neoplasia type 1 in Northern Finland; clinical features and genotype-phenotype correlation. Eur J Endocrinol 157:285–294CrossRefPubMed
7.
go back to reference De Laat JM, Dekkers OM, Pieterman CRC, Kluifjhout WP, Hermus AR, Pereira AM, van den Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, de Herder WW, Valk GD (2015) Long-term natural course of pituitary tumors in patients with MEN1: results from the DutchMEN1 Study Group [DMSG]. J Clin Endocrinol Metab 100:3288–3296CrossRefPubMed De Laat JM, Dekkers OM, Pieterman CRC, Kluifjhout WP, Hermus AR, Pereira AM, van den Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, de Herder WW, Valk GD (2015) Long-term natural course of pituitary tumors in patients with MEN1: results from the DutchMEN1 Study Group [DMSG]. J Clin Endocrinol Metab 100:3288–3296CrossRefPubMed
8.
go back to reference Beckers A, Betea D, Socin HV, Stevenaert A (2003) The treatment of sporadic versus MEN1-related pituitary adenomas. J Intern Med 253:599–605CrossRefPubMed Beckers A, Betea D, Socin HV, Stevenaert A (2003) The treatment of sporadic versus MEN1-related pituitary adenomas. J Intern Med 253:599–605CrossRefPubMed
9.
go back to reference Syro LV, Scheithauer BW, Kovacs K, Toledo RA, Londoño FJ, Ortiz LD, Rotondo F, Horvath E, Uribe H (2012) Pituitary tumors in patients with MEN1 syndrome. Clinics 67(S1):43–48CrossRefPubMedPubMedCentral Syro LV, Scheithauer BW, Kovacs K, Toledo RA, Londoño FJ, Ortiz LD, Rotondo F, Horvath E, Uribe H (2012) Pituitary tumors in patients with MEN1 syndrome. Clinics 67(S1):43–48CrossRefPubMedPubMedCentral
10.
go back to reference Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML (2012) Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 97:2990–3011CrossRefPubMed Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML (2012) Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 97:2990–3011CrossRefPubMed
11.
go back to reference Gillam MP, Molitch ME (2010) Prolactin. In: Melmed S (ed) The Pituitary, 3rd edn. Elsevier Inc., San Diego, pp 119–166 Gillam MP, Molitch ME (2010) Prolactin. In: Melmed S (ed) The Pituitary, 3rd edn. Elsevier Inc., San Diego, pp 119–166
12.
go back to reference Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N, Turner HE, Wass JAH (2006) Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol 65:524–529CrossRef Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N, Turner HE, Wass JAH (2006) Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol 65:524–529CrossRef
13.
go back to reference Serri O, Robert F, Pelletier G, Beauregard H, Hardy J (1987) Hyperprolactinemia associated with clinically silent adenomas: endocrinologic and pathologic studies; a report of two cases. Fertil Steril 47:792–796CrossRefPubMed Serri O, Robert F, Pelletier G, Beauregard H, Hardy J (1987) Hyperprolactinemia associated with clinically silent adenomas: endocrinologic and pathologic studies; a report of two cases. Fertil Steril 47:792–796CrossRefPubMed
14.
go back to reference Losa M, Mortini P, Giovanelli M (2004) A non-functioning pituitary adenoma initially mimicking a microprolactinoma: the case for long-term follow-up of patients with mild hyperprolactinemia? J Endocrinol Invest 27:367–370 Losa M, Mortini P, Giovanelli M (2004) A non-functioning pituitary adenoma initially mimicking a microprolactinoma: the case for long-term follow-up of patients with mild hyperprolactinemia? J Endocrinol Invest 27:367–370
15.
go back to reference Arafah BM, Prunty D, Ybarra J, Hlavin ML, Selman WR (2000) The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas. J Clin Endocrinol Metab 85:1789–1793PubMed Arafah BM, Prunty D, Ybarra J, Hlavin ML, Selman WR (2000) The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas. J Clin Endocrinol Metab 85:1789–1793PubMed
16.
go back to reference Pontiroli AE, Falsetti L (1984) Development of pituitary adenoma in women with hyperprolactinaemia: clinical, endocrine, and radiological characteristics. B.M.J 288:515–518CrossRef Pontiroli AE, Falsetti L (1984) Development of pituitary adenoma in women with hyperprolactinaemia: clinical, endocrine, and radiological characteristics. B.M.J 288:515–518CrossRef
17.
go back to reference Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68:412–418CrossRefPubMed Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68:412–418CrossRefPubMed
18.
go back to reference Sluijmer AV, Lappöhn RE (1992) Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia. Fertil Steril 58:72–77CrossRefPubMed Sluijmer AV, Lappöhn RE (1992) Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia. Fertil Steril 58:72–77CrossRefPubMed
19.
go back to reference Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JAH (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273–288CrossRefPubMed Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JAH (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273–288CrossRefPubMed
20.
go back to reference Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho L, Wass J, Giustina A (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 65:265–273CrossRef Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho L, Wass J, Giustina A (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 65:265–273CrossRef
21.
go back to reference Chuang E, Molitch M (2005) Need for periodic pituitary imaging in patients with MEN I syndrome. Presented at the 9th international pituitary congress, San Diego, June, 2005, Abstract #15. Pituitary 7 4 Chuang E, Molitch M (2005) Need for periodic pituitary imaging in patients with MEN I syndrome. Presented at the 9th international pituitary congress, San Diego, June, 2005, Abstract #15. Pituitary 7 4
Metadata
Title
Pituitary tumors in MEN1: do not be misled by borderline elevated prolactin levels
Authors
Alina Livshits
Jelena Kravarusic
Ellie Chuang
Mark E. Molitch
Publication date
01-12-2016
Publisher
Springer US
Published in
Pituitary / Issue 6/2016
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-016-0752-z

Other articles of this Issue 6/2016

Pituitary 6/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.